http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2643811-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb972790dff0b1a791b74fbaacc1a424 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-28 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
| filingDate | 2013-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2dc64902a0bcf0abe58dd1884bef857a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b5aa1169dd38bbd55506fbdedfa7630 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f43675b3e1a62e9b2b97685624b29d51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eb1d7a9813537c2c103e0b041b33e90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e703fdfb067880d6bc4db32b21f5f6be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5736601c5bc5540d78a174e498b4567c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1e99d9fb248532f555452d30cdd906e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_073d6e4467b2821a0655ed198f86400d |
| publicationDate | 2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2643811-C2 |
| titleOfInvention | Method for production of hydroxylated cyclopentyl pyrimidine compounds |
| abstract | FIELD: pharmacology. n SUBSTANCE: compounds of formula I can be used to prepare compounds possessing the properties of an ACT kinase inhibitor for treatment of diseases such as cancer. The method for preparation of a compound of formula I comprises cyclising of a compound of formula II or a salt thereof, wherein R 1 is t-butoxycarbonyl; R 2 is -COOR a , where R a is hydrogen or unsubstituted C 1-4 alkyl, or R 2 is-CONR a R b , where R a is unsubstituted C 1-4 alkyl and R b is -OR c , phenyl; or R a and R b are taken together with the atom to which they are attached to form a 5-7 membered heterocyclyl, further comprising an oxygen atom; R c is C 1-4 alkyl; and M is Li or Mg. At that, a compound of formula II or a salt thereof obtained by contacting of a compound of formula III or a salt thereof, wherein R 3 is bromine or iodine, with a magnesium or lithium metal-containing agent, for example alkyl magnesium halide, is used. The compound of formula III is usually prepared by reacting a compound of formula IV or a salt thereof with compound to produce a compound of formula V or a salt thereof, wherein R 4 is -Cl or -OH, R 1 and R 2 have the values indicated above. The invention also relates to new intermediates, a compound of formula III and a compound of formula IV. n EFFECT: method allows to obtain products on an industrial scale with comparable or increased yield and quality of products. n 22 cl, 1 tbl, 6 ex n , |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2712224-C2 |
| priorityDate | 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 202.